Osiris offloads Prochymal to Mesoblast
This article was originally published in Scrip
Executive Summary
Osiris Therapeutics has sealed a deal with fellow regenerative medicine company Mesoblast which could see it receive up to $100m for stem cell technology that includes its controversial "off-the-shelf" therapy Prochymal. However, only $35m is guaranteed cash: an additional $15m will be paid in Mesoblast stock and the remainder of the $100m depends on success in the clinic and US/EU approvals.